The phosphodiesterase type-5 (PDE-5) inhibitorssildenafil (Viagra), vardenafil (Levitra) and tadalafil (Cialis)-are efficacious treatments for male erectile dysfunction. 1 By inhibiting PDE-5, which is abundant in penile vascular smooth muscle cells, these drugs decrease the breakdown of intracellular cyclic guanosine monophosphate (the formation of which is initiated by nitric oxide release with sexual stimulation), resulting in relaxation of the smooth muscle cells surrounding the sinusoids of the corpus cavernosa. 2 Consequently, there is a fall in the penile arterial resistance, leading to engorgement of the sinusoids with blood and, provided there is adequate compression of the subtunical venous plexus, penile erection. Given that PDE-5 inhibitors are well tolerated, with few side effects, they have become the first-line treatment for male erectile dysfunction and rank among the best-selling drugs worldwide. 1, 3 Since the introduction of sildenafil 10 years ago, there have been a number of reports of patients developing acute monocular visual loss due to nonarteritic anterior ischemic optic neuropathy (NAION) within hours of ingesting a PDE-5 inhibitor. These reports have received a significant amount of media attention, although the academic community has debated whether a cause-effect relationship truly exists. In this paper, we will review NAION and then discuss the evidence for and against NAION occurring as a complication of PDE-5 inhibitor use. A separate, unrelated transient visual disturbance occurs on a retinal basis with PDE-5 inhibitor use and we begin by briefly reviewing this benign side effect.
Transient visual side effects of PDE-5 inhibitors
It is well documented that PDE-5 inhibitors can produce transient visual symptoms, such as a change in color hue perception, where the patient may perceive a blue tinge to the visual world (cyanopsia), and increased sensitivity to light. 4, 5 These side effects, which occur most commonly with sildenafil, are thought to be consequent to weak PDE-6 inhibition. PDE-6, a close isozyme of PDE-5, is involved in the activation and modulation of the phototransduction cascade in retinal cone and rod cells. 6 Electroretinogram (ERG) changes have been observed following ingestion of sildenafil, suggesting dysfunction of photoreceptors, but the changes are short-lived and fully reversible. 7, 8 Despite the ERG changes, several studies assessing automated visual fields following ingestion of PDE-5 inhibitors have failed to demonstrate any statistically significant alteration, [9] [10] [11] even with blue-onyellow stimuli, although transient reversible visualfield defects were noted in one healthy young subject following ingestion of sildenafil in one of these studies. 9 It is of interest to note that some recessively inherited forms of retinitis pigmentosa, a common degenerative retinal disease, are caused by mutations in PDE-6. 12 In mice heterozygous for a mutation causing absence of the g-subunit of PDE-6, it was found that reversible dose-dependent ERG changes occurred following treatment with sildenafil. 13 Although further study is required, these findings imply that PDE-5 inhibitors could have a significant impact on retinal function in patients with retinitis pigmentosa and even in carriers of PDE-6 mutations. Thus, use of PDE-5 inhibitors is currently not recommended in patients with retinitis pigmentosa.
Nonarteritic anterior ischemic optic neuropathy
Anterior ischemic optic neuropathy is the most frequent cause of acute optic neuropathy in older adults in the Western world. 14 The nonarteritic variant (NAION) has an annual incidence of 2.3-10.2 per 100 000 adults aged over 50 years in the United States. 15, 16 It typically produces a rapid onset of painless monocular visual loss that worsens over hours to days, with associated optic disk edema that can be hyperemic (Figure 1c) or pallid, 17 and a relative afferent pupillary defect. An altitudinal visual-field defect (which respects the horizontal meridian), more often involving the inferior half of the visual field, is commonly detected on perimetry (Figure 1d) , although a number of other visual-field defects can also occur. Visual acuity can range from 20/20 (if the field defect does not involve central vision) to no light perception, with up to 50% of affected patients having an acuity of 20/64 or better. 18 The optic disk edema gradually resolves in the weeks after onset, with the disk ultimately becoming pale and atrophic (Figure 1e ). Acuity and fields also stabilize (and can sometimes improve) days or even weeks after onset (Figure 1f) .
Anterior ischemic optic neuropathy occurs due to hypoperfusion and ischemia of the optic nerve head. 19 In contrast with the arteritic form (AAION), where giant cell (temporal) arteritis causes inflammatory occlusion of the small vessels supplying the optic nerve head, the pathogenesis of the nonarteritic form (NAION) is not well understood. 19 As it is associated with diabetes and hypertension, it might occur as a result of atherosclerotic changes in these vessels, although the association with other atherosclerosis risk factors, such as smoking and dyslipidemia, is not as consistent. 18 As many patients with NAION wake with the visual loss, 20 it has been proposed that nocturnal hypotension could be an important etiologic factor. 21 A variety of other factors, such as vasospasm and impaired vascular autoregulation, might be important in the pathogenesis. 19 Consistently, however, the fellow (unaffected) eye has a small optic nerve head with a small or absent physiologic cup ( Figure 1a ); this anatomic variant, which is associated with normal visual acuity and fields (Figure 1b ), is well established as a marker for increased risk of NAION, although the exact means by which it influences pathogenesis is unclear. 19, 22 The presence of this so-called 'disk at risk', which is usually a bilateral finding and more common in Caucasians, 23 could also partly explain the increased risk of NAION developing in the fellow eye.
At present, there is no effective treatment for NAION, although a number of therapies have been studied with none being found to be clearly beneficial.
14 In a multicenter randomized trial, optic nerve sheath decompression was found to be ineffective and possibly harmful. 24 Although there is no proven prophylactic therapy to prevent NAION, most authors advocate control of vascular risk factors and the use of antiplatelet therapy, as there is about a 15% chance of recurrence in the fellow eye in the first 5 years following the initial presentation. 25 NAION must be differentiated from the arteritic variant (AAION), which is caused by giant cell (temporal) arteritis. 17 AAION also causes a rapid onset of severe monocular visual loss, but it is usually preceded by other symptoms, such as headache, scalp tenderness and jaw claudication. Although inflammatory markers (such as the erythrocyte sedimentation rate and C-reactive protein) are typically raised, the definitive diagnostic test remains temporal artery biopsy. Differentiation of AAION from NAION is crucial, as the patient with AAION may go on to develop severe visual loss on the other side if corticosteroid therapy is not commenced in a timely fashion. 14 
NAION with PDE-5 inhibitors
There are a number of reports of patients developing unilateral or, in one case, bilateral NAION within hours of ingesting a PDE-5 inhibitor, in most cases NAION with PDE-5 Inhibitors MJ Thurtell and RL Tomsak sildenafil (Table 1) . [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] Most of the evidence suggesting an association between NAION and use of PDE-5 inhibitors is from case reports or series published since 2000. A causative link has been proposed on the basis that the visual loss developed, in most of these cases, within 24 h of ingesting a PDE-5 inhibitor. In one case, a 67-year-old man with hypercholesterolemia had four episodes of transient monocular inferior visual-field loss occurring within 2 h of taking tadalafil. 34 After his fifth dose of the drug, he developed permanent monocular inferior visual-field loss due to NAION. In another case, a 36-year-old man on hemodialysis for end-stage renal failure, who had also had prior problems with hypotension, awoke with monocular visual loss due to NAION after taking his first dose of sildenafil the night before. 37 He went on to develop a cilioretinal artery and central retinal vein occlusion on the same side within days. Then, 4 months later, he again awoke with monocular visual loss due to NAION, this time on the other side, after taking another dose of sildenafil the night before. In a third case, a 63-year-old man with hypertension had a stepwise enlargement of a monocular visual-field defect, secondary to NAION, following three successive doses of sildenafil. 40 Although these cases strongly suggest a cause-effect relationship, as NAION developed or progressed following rechallenge with the drug, case reports and series do not explicitly test for an association between exposure and outcome, and there is no control for confounding factors.
In a retrospective age-and sex-matched casecontrol study, men with NAION were no more likely to report a history of PDE-5 inhibitor use than controls. 41 However, patients with a history of myocardial infarction who were using PDE-5 inhibitors had a statistically significant increase in their risk of NAION, while there was a trend toward an increased risk of NAION that was not statistically significant in those with a history of hypertension. 41 Although this study has received criticism because of its small sample size and the possibility that bias (for example, selection, interviewer or recall bias) may have influenced the results, 42, 43 the findings suggest that patients with a history of myocardial The right optic disk is pink and flat, but has a very small physiologic cup, indicating that it is a 'disk at risk' (a). Automated perimetry, using the Humphrey 30-2 SITA-fast protocol (which assesses the central 301 of the visual field), shows a normal visual field (b), with the dark spot in the temporal field being the physiologic blind spot. Acutely, the left optic disk appears swollen and hyperemic, with hemorrhage at the superior and temporal disk margin (c). Automated perimetry shows diffuse visual-field loss, more marked in the inferior aspect of the field (d). On review at 3 months, the optic disk swelling has resolved and the disk appears diffusely pale and atrophic (e). Automated perimetry shows improvement in the superior visual field, with a persistent inferior altitudinal defect (f).
NAION with PDE-5 Inhibitors MJ Thurtell and RL Tomsak infarction or hypertension could have an increased risk of NAION if they use PDE-5 inhibitors.
In a retrospective cohort study using the National Veterans Health Administration's pharmacy and clinical databases, the relative risk of NAION among 480 000 men prescribed a PDE-5 inhibitor was 1.02, whereas the relative risk of 'possible' NAION (defined as papillitis and optic neuritis) was 1.34. 44 When combined, the risk of NAION or 'possible' NAION was found to be marginally significant, with a relative risk of 1.10 (95% confidence intervals of 1.02-1.20). 44 The interpretation of these findings is limited because the authors were unable to verify the accuracy of diagnoses, there were no data on whether or not the PDE-5 inhibitor was actually taken (indeed, a patient could have obtained a PDE-5 inhibitor from another source, and its use might not have been disclosed or documented), and there were no data available on the temporal relationship between PDE-5 inhibitor use and the onset of visual loss. The significance of the increased risk of NAION or 'possible' NAION is especially in doubt, given that patients with other diagnoses were almost certainly included in the analysis.
The mechanism by which PDE-5 inhibitors might produce NAION is undefined. Several patients with NAION occurring in the context of PDE-5 inhibitor use were noted to have a 'disk at risk' on examination of the fellow eye and other vascular risk factors, such as hypertension and diabetes, suggesting a baseline increased risk of developing NAION ( Table 1) . As PDE-5 inhibitors are known to mildly reduce systemic blood pressure, 45 and they are most likely to be taken prior to sexual activity in the evening, it has been postulated that they might increase the risk of NAION by exacerbating nocturnal hypotension. 46, 47 This hypothesis is supported by the observation that a considerable number of the patients with NAION following PDE-5 inhibitor use awoke with visual loss the morning after drug ingestion (Table 1) . Thus, it may be that, in a patient who has a 'disk at risk', small vessel disease due to atherosclerosis risk factors, taking medications with an antihypertensive effect, a further drop in blood pressure following PDE-5 inhibitor use could be the precipitating factor for development of NAION. In a double-blind, randomized, crossover trial in healthy men receiving sildenafil and placebo, optic nerve rim circulation was assessed using laser Doppler flowmetry, with no significant change observed after receiving a dose of sildenafil. 48 However, this study has received criticism, 49 as laser Doppler flowmetry is predominantly sensitive to detecting blood flow in the superficial layers of the optic nerve, whereas it is less sensitive to detecting blood flow in the NAION with PDE-5 Inhibitors MJ Thurtell and RL Tomsak deeper layers, which supply the optic disk. 50 In the absence of a more reliable technique by which to measure blood flow to the optic nerve head, the effect of PDE-5 inhibitors on the perfusion of the optic nerve head remains unknown.
Supporting the argument against the presence of a cause-effect relationship is the low incidence of NAION in the large population of men who have used PDE-5 inhibitors worldwide. In a review of data from over 100 clinical trials of sildenafil efficacy, only one patient was found to have developed NAION, giving an estimated incidence of 2.8 per 100 000 patient-years of exposure to sildenafil, 51 which is within the annual incidence range reported in prior population studies of NAION. 15, 16 43 especially given that NAION is not a common condition in the first place, and that PDE-5 inhibitor use prior to the onset of NAION may not have been reported or recognized as being a potential contributing factor by patient or doctor, resulting in a significant number of unreported cases. 47 Nevertheless, as a number of the patients developing NAION in the context of PDE-5 inhibitor use had other risk factors for NAION, such as a 'disk at risk', vascular risk factors or a prior history of NAION in the fellow eye (Table 1) , it has been suggested that PDE-5 inhibitor use may have been coincidental rather than causative. 54 Not all reported cases have had risk factors for NAION (Table 1) . In one case, a 6-year-old girl, who had previously undergone repair of aortic coarctation, a mitral valve replacement, and a pacemaker placement, later developed a unilateral optic neuropathy while receiving regular treatment with sildenafil for pulmonary hypertension. 38 The timing of onset of the visual loss was unclear but, as no other cause was established, the authors speculated that the child had developed NAION. Given that NAION is extremely rare in children and that the girl did not have other risk factors for NAION, such as a 'disk at risk' or hypotension, a possible link with sildenafil therapy was postulated. As sildenafil gains popularity as a treatment for pulmonary hypertension in the pediatric population, it will be of interest to see if an increased risk of NAION is demonstrated in this population in the coming years.
Recommendations
Given the uncertainty about whether a cause-effect relationship truly exists, the US Food and Drug Administration has issued a statement regarding visual loss in the context of PDE-5 inhibitor use. Although a causative link between PDE-5 inhibitor use and NAION has not been implied, they advise patients who are considering using PDE-5 inhibitors to inform their health-care professional if they have ever had severe monocular visual loss, which might indicate a prior episode of NAION and thereby place them at risk for recurrence in the fellow eye, and they also advise patients to cease PDE-5 inhibitor use and seek immediate medical attention if they experience a sudden decrease in vision in one or both eyes. 53 In our opinion, urgent referral to a neuro-ophthalmologist or ophthalmologist is mandatory in the event of sudden visual loss, so as to ensure that the patient undergoes investigations and receives appropriate treatment in a timely fashion (this is particularly important in cases of AAION, where corticosteroid therapy could preserve vision in the fellow eye).
Given the potentially devastating visual consequences of NAION and the lack of an available effective treatment, we would advise that patients with any risk factor for NAION be warned of the potential for this rare complication prior to prescription of the drug. Furthermore, we would advise caution in prescribing PDE-5 inhibitors for patients with a prior history of NAION or for those with a 'disk at risk' (this finding is easy to detect using the direct ophthalmoscope or by referral to an eye care professional).
PDE-5 inhibitors are contraindicated in patients with retinitis pigmentosa, as they weakly inhibit retinal PDE-6 and could have a deleterious effect on retinal function. However, given there are no published reports of NAION occurring in patients with other active optic nerve or retinal diseases, such as glaucoma, diabetic retinopathy and agerelated macular degeneration, there are currently no guidelines regarding the use of PDE-5 inhibitors in patients with these conditions. We recommend consultation with the patient's ophthalmologist in such cases, as further visual loss due to NAION could leave the patient with a severe visual deficit.
Summary
No definite causative link between PDE-5 inhibitor use and NAION has been established to date. Patients with a prior history of NAION, who are at increased risk of a second episode of NAION, and those with risk factors for NAION, including anatomic risk factors such as a 'disk at risk' and vascular risk factors such as hypertension and NAION with PDE-5 Inhibitors MJ Thurtell and RL Tomsak diabetes, or a history of myocardial infarction, might be at increased risk of developing NAION with PDE-5 inhibitor use. As vascular risk factors are also implicated in the pathogenesis of organic erectile dysfunction, the clinician must weigh up the potential benefits and risks of prescribing PDE-5 inhibitors to these patients. All patients with a prior history of NAION or risk factors for NAION, in particular a 'disk at risk', should at least be warned of the potential for this rare complication prior to prescription of the drug. Any patient developing acute visual loss in association with PDE-5 inhibitor use should be immediately referred to a neuroophthalmologist or ophthalmologist for further assessment and management.
